Type-based Boron Supplement segmentation distinguishes capsules, tablets, powders, and liquids, each shaping unit economics differently. Capsules dominate value share because they allow 2–5 mg precision dosing and command a 25–35 % retail premium, making them the default in bone-health positioned lines. Tablets remain cost leaders for high-volume contract manufacturers, compressing boron citrate or boron glycinate to ≥90 % assay, but price erosion is >4 % CAGR. Powders, sold in bulk or stick packs, serve the sports-nutrition niche where flexible 1 g–3 g loading is required; gross margins are compressed by 8–10 pp versus capsules yet volumes compensate through 300 g–500 g SKUs. Liquid boron, usually as glycerol-borate, is the fastest-growing subsegment, driven by pediatric and geriatric compliance considerations, with per-dose value 2.3× that of tablets. Overall, type choices determine channel access—capsules and liquids are shelf-friendly in pharmacies, whereas powders remain e-commerce centric.